Pluristem Therapeutics, Inc. (PSTI) Given Average Recommendation of “Hold” by Brokerages
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has earned an average rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $3.83.
Several research analysts have recently commented on PSTI shares. Seaport Global Securities reaffirmed a “buy” rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a report on Friday, October 6th. Maxim Group reaffirmed a “buy” rating and issued a $2.00 price target on shares of Pluristem Therapeutics in a report on Tuesday, September 5th. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 17th. ValuEngine upgraded shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 22nd.
Shares of Pluristem Therapeutics (NASDAQ:PSTI) opened at 1.68 on Tuesday. The stock’s market capitalization is $163.75 million. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $2.12. The stock has a 50 day moving average of $1.61 and a 200-day moving average of $1.37.
A number of large investors have recently modified their holdings of the stock. Heritage Investors Management Corp bought a new stake in Pluristem Therapeutics in the 3rd quarter valued at about $113,000. Jane Street Group LLC lifted its position in Pluristem Therapeutics by 62.4% in the 1st quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 41,796 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in Pluristem Therapeutics by 9.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock valued at $1,911,000 after purchasing an additional 129,000 shares during the last quarter. Hedge funds and other institutional investors own 4.54% of the company’s stock.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.